Blue Earth Therapeutics is highlighting clinical study results that suggest that its radiopharmaceutical labeled with lutetium-177 (Lu-177) is effective for treating metastatic, castrate-resistant prostate cancer.
The company's LU-177 rhPSMA-10.1 (radiohybrid prostate-specific membrane antigen [PSMA]) showed statistically significant tumor growth suppression in comparison to LU-177 PSMA ligand, according to research presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 meeting.
The potential therapeutic efficacy of the two radiopharmaceuticals was compared in a PSMA-expressing prostate cancer xenograft model. LU-177 rhPSMA-10.1 significantly reduced tumor volume compared with the control ligand. It also showed a statistically significant suppression of tumor growth compared to both non-radiolabeled rhPSMA-10.1 and the control ligand at both 14 days after treatment and 35 days after treatment.
At the meeting, Blue Earth also announced that the phase III trial of its investigational fluciclovine F-18-labeled radiohybrid PSMA-targeted PET agent (F-18 rhPSMA-7.3) in recurrent prostate cancer showed high inter- and intrareader agreement: Interreader agreement was more than 75% overall, while intrareader agreement was more than 85% overall, according to the company.
